Neue Therapieoptionen bei
fortgeschrittenen Schilddrüsenkarzinomen

M J Willhauck; M Schott; M C Kreissl; M Fassnacht; C Spitzweg

doi:10.1055/s-0031-1280531

DMW – Klinischer Fortschritt, Inhaltsverzeichnis

Dtsch Med Wochenschr 2011; 136(22): 1165-1168
DOI: 10.1055/s-0031-1280531

Endokrinologie und Diabetologie | Commentary

Endokrinologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen

New therapeutic options for advanced thyroid cancerM. J. Willhauck¹ , M. Schott² , M. C. Kreissl³ , M. Fassnacht⁴ , C. Spitzweg¹

¹Medizinische Klinik und Poliklinik II – Campus Großhadern, Klinikum der Universität München, Ludwig-Maximilians-Universität München
²Klinik für Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf
³Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg
⁴Medizinische Klinik und Poliklinik I, Schwerpunkt Endokrinologie – Diabetologie, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg

Abstract

Schlüsselwörter

Schilddrüsenkarzinom - Multityrosinkinase-Inhibitoren - Sorafenib - Sunitinib - Vandetanib

Keywords

thyroid cancer - multi-tyrosine kinase inhibitors - sorafenib - sunitinib - vandetanib

Volltext

Referenzen

Literatur

1 Bible K C, Suman V J, Molina J R. et al . Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers. Lancet Oncol. 2010; 11 962-972
2 Carr L L, Mankoff D A, Goulart B H. et al . Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16 5260-5268
3 Cohen E EW, Needles B M, Cullen K J. et al . Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol. 2008; 26 (Suppl.) Abstract 6025
4 Cohen E EW, Rosen L S, Vokes E E. et al . Axitinib is an active traetment for all histologic subtypes of advanced thyroid cancer. J Clin Oncol. 2008; 26 4708-4713
5 De Souza J A, Busaidy N, Zimrin A. et al . Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol. 2010; 28 (Suppl.) Abstract 5504
6 Gupta-Abramson V, Troxel A B, Nellore A. et al . Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008; 26 4714-4719
7 Hoftijzer H, Heemastra K A, Morreau H. et al . Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009; 161 923-931
8 Kloos R T, Ringel M D, Knopp M V. et al . Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009; 27 1675-1684
9 Kurzrock R, Cohen E E, Sherman S I. et al . Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL 184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol. 2010; 28 (Suppl.) Abstract 5502
10 Lam E T, Ringel M D, Kloos R T. et al . Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010; 28 2323-2330
11 Ravaud A, de la Fouchardiere C, Courbon F. et al . Sunitinib in patients with refractory advanced thyroid cancer. J Clin Oncol. 2008; 26 Suppl Abstract 6058
12 Robinson B G, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010; 95 2664-2671
13 Schlumberger M, Elisei R, Bastholt L. et al . Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009; 27 3794-3801
14 Sherman S I, Wirth L J, Droz J -P. et al . Motesanib diphosphate in progressive differentiated thyroid cancer. New Engl J Med. 2008; 359 31-42
15 Wells S A, Gosnell J E, Gagel R F. et al . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010; 28 767-772
16 Wells S A, Robinson B G, Gagel R F. et al . Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC). J Clin Oncol. 2010; 28 (Suppl.) Abstract 5503
17 Woyach J A, Shah M H. New therapeutic advances in the management of progressive thyroid cancer. Endocrine Rel Cancer. 2009; 16 715-731

Prof. Dr. Christine Spitzweg

Medizinische Klinik und Poliklinik II
Klinikum der Universität München – Campus Großhadern

Marchioninistr. 15

81377 München

Telefon: 089/7095-0

Fax: 089/7095-8887

eMail: Christine.Spitzweg@med.uni-muenchen.de